Oral Abstract: MDS-445 Magrolimab In Combination with Azacitidine for Patients with Untreated Higher-Risk Myelodysplastic Syndromes (HR MDS): 5F9005 Phase 1b Study Results

David Sallman; Monzr Al Malki; Adam Asch; Eunice Wang; Joseph Jurcic; Terrence Bradley; Ian Flinn; Daniel Pollyea; Suman Kambhampati; Tiffany Tanaka; Joshua Zeidner; Guillermo Garcia-Manero; Deepa Jeyakumar; Lin Gu; Anderson Tan; Mark Chao; Carol O'Hear; Indu Lal; Paresh Vyas; Naval Daver

doi:10.1016/S2152-2650(22)00690-5

Back

Oral Abstract: MDS-445 Magrolimab In Combination with Azacitidine for Patients with Untreated Higher-Risk Myelodysplastic Syndromes (HR MDS): 5F9005 Phase 1b Study Results

Journal article

Peer reviewed

Oral Abstract: MDS-445 Magrolimab In Combination with Azacitidine for Patients with Untreated Higher-Risk Myelodysplastic Syndromes (HR MDS): 5F9005 Phase 1b Study Results

David Sallman, Monzr Al Malki, Adam Asch, Eunice Wang, Joseph Jurcic, Terrence Bradley, Ian Flinn, Daniel Pollyea, Suman Kambhampati, Tiffany Tanaka, …

Clinical lymphoma, myeloma and leukemia, Vol.22, p.S115

2022-10

DOI: https://doi.org/10.1016/S2152-2650(22)00690-5

Appears in Miller School of Medicine - Latest Publications

Metrics

2 Record Views

Details

Title: Oral Abstract: MDS-445 Magrolimab In Combination with Azacitidine for Patients with Untreated Higher-Risk Myelodysplastic Syndromes (HR MDS): 5F9005 Phase 1b Study Results
Creators: David Sallman - Moffitt Cancer Center
Monzr Al Malki
Adam Asch
Eunice Wang
Joseph Jurcic
Terrence Bradley
Ian Flinn
Daniel Pollyea
Suman Kambhampati
Tiffany Tanaka
Joshua Zeidner
Guillermo Garcia-Manero
Deepa Jeyakumar
Lin Gu
Anderson Tan
Mark Chao
Carol O'Hear
Indu Lal
Paresh Vyas
Naval Daver
Publication Details: Clinical lymphoma, myeloma and leukemia, Vol.22, p.S115
Academic Unit: UMMG Dept of Medicine - Hematology/Oncology; Miller School of Medicine
Language: English
Resource Type: Journal article
Record Identifier: 991031786674402976